Tonix Pharma (TNXP) AI Stock Analysis

• Market Cap: $137.56M
• Dividend Yield: N/A
• Average Volume (3M): 1.22M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.97
• Revenue Growth: 29.94%
• EPS Growth: -241.81%
• Country: US
• Employees: 81
• Sector: Healthcare
• Sector Strength: 60
• Industry: Biotechnology
• EPS (TTM): -29.46
• Shares Outstanding: 6,877,816
• 10 Day Avg. Volume: 636,445
• 30 Day Avg. Volume: 1,221,454
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: -0.65
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -38.60
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $70.00
• Price Target Upside: 257.51% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Tonix Pharma's stock score reflects a company in its growth phase with substantial revenue increases and strategic advancements in product development. However, significant challenges remain in profitability and cash flow sustainability, necessitating ongoing external funding. Positive corporate events provide some optimism, yet weak technical indicators and valuation concerns cap the overall score.

Tonix Pharma Business Overview & Revenue Model

Company Description

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

How the Company Makes Money

Tonix Pharmaceuticals generates revenue primarily through the development and commercialization of its pharmaceutical products. As a clinical-stage company, its main revenue streams are expected to come from upfront payments, milestone payments, and royalties from partnerships or licensing agreements with larger pharmaceutical companies. These collaborations are crucial as they provide the financial resources and market access needed to advance the development and commercialization of its drug candidates. Additionally, Tonix may receive grant funding or government support for research and development efforts, particularly for projects in the public health domain, such as their COVID-19 vaccine and therapeutic programs. However, as of now, the company does not have any products approved for sale, and its revenue generation is contingent upon the successful development and commercialization of its pipeline candidates.

Tonix Pharma Financial Statement Overview

Summary

Tonix Pharma is in a growth phase with significant revenue gains but faces profitability challenges. The balance sheet is strong with low debt, yet cash flow issues persist due to negative free cash flow and reliance on external funding.

Income Statement

Tonix Pharma has shown substantial revenue growth from prior years, with total revenue increasing significantly from $0 to $10.09 million in 2024. However, profitability remains a challenge as indicated by negative EBIT and EBITDA margins. The net profit margin is nonexistent due to zero net income, suggesting the company is still in a heavy investment phase, typical for the biotechnology industry.

Balance Sheet

The company's balance sheet shows a healthy equity base with a debt-to-equity ratio of approximately 0.06, indicating low financial leverage. The equity ratio is strong at 85.7%, reflecting a robust capital structure. However, consistent net losses over the years suggest potential pressures on financial sustainability if cash reserves dwindle without profitability improvements.

Cash Flow

Cash flow analysis reveals a negative free cash flow, though the company has improved its operating cash flow situation compared to previous years. The significant financing cash flow indicates reliance on external funding to support operations. The cash flow to net income ratios are not meaningful due to the lack of net income.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
10.09M	7.77M	0.00	0.00	0.00
	Gross Profit
2.33M	3.03M	-112.09M	-92.31M	-50.51M
	EBIT
-136.70M	-118.38M	-112.09M	-92.31M	-50.51M
	EBITDA
-71.73M	-114.09M	-110.84M	-92.26M	-50.48M
	Net Income Common Stockholders
-130.04M	-116.66M	-116.88M	-92.29M	-52.17M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
98.78M	24.95M	120.23M	178.66M	77.07M
	Total Assets
162.89M	154.46M	225.69M	240.90M	98.18M
	Total Debt
8.12M	9.81M	760.00K	956.00K	1.31M
	Net Debt
-90.66M	-15.13M	-119.47M	-177.70M	-75.76M
	Total Liabilities
23.33M	48.93M	18.51M	22.18M	10.54M
	Stockholders Equity
139.56M	105.53M	207.18M	218.72M	87.65M
Cash Flow		Free Cash Flow
-61.05M	-109.90M	-146.20M	-110.86M	-57.13M
	Operating Cash Flow
-60.92M	-102.00M	-98.05M	-75.56M	-48.57M
	Investing Cash Flow
-120.00K	-29.07M	-48.15M	-35.31M	-8.56M
	Financing Cash Flow
134.87M	36.52M	87.84M	212.49M	123.11M

Tonix Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 19.58
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TNXP, the sentiment is Positive. The current price of 19.58 is above the 20-day moving average (MA) of 17.32, above the 50-day MA of 16.54, and below the 200-day MA of 23.63, indicating a neutral trend. The MACD of 0.23 indicates Negative momentum. The RSI at 56.50 is Neutral, neither overbought nor oversold. The STOCH value of 79.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TNXP.

Tonix Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CHRS	57 Neutral	$127.49M	5.85	0.51%	―	3.78%	―
CLLS	57 Neutral	$118.22M	―	-34.08%	―	5397.35%	77.93%
Sector *	52 Neutral	$5.35B	3.83	-41.61%	2.85%	17.10%	1.22%
TNXP	50 Neutral	$137.56M	―	-106.12%	―	29.94%	-241.81%
NKTR	48 Neutral	$139.95M	―	-124.10%	―	9.22%	60.01%
TIL	34 Underperform	$94.97M	―	-37.51%	―	―	52.54%
EDIT	33 Underperform	$137.28M	―	-98.10%	―	-58.64%	-40.05%

Tonix Pharma Corporate Events

Tonix Pharma Unveils Promising Cancer Treatment Data

On April 28, 2025, Tonix Pharmaceuticals presented promising data at the AACR Annual Meeting, demonstrating that their fusion protein mTFF2-MSA, combined with an anti-PD1 antibody, effectively activates cancer-killing CD8+ T Cells and reduces immunosuppression in tumor microenvironments in animal models. This development highlights Tonix’s potential impact in cancer treatment, particularly with their TNX-1700 candidate, which is in preclinical stages for gastric and colorectal cancers.

Spark’s Take on TNXP Stock

According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.

Tonix Pharma’s stock score reflects a growth phase with substantial revenue increases and strategic advancements in product development. However, the company faces significant profitability challenges and reliance on external funding, impacting financial sustainability. Positive corporate events provide some optimism, yet technical indicators remain weak, capping the overall score.

To see Spark’s full report on TNXP stock, click here.

Tonix Pharma Presents Promising Vaccine Data at Congress

On April 23, 2025, Tonix Pharmaceuticals presented promising preclinical data at the World Vaccine Congress in Washington. Their TNX-801 vaccine candidate showed efficacy in protecting animals against mpox and rabbitpox, including in immunocompromised subjects, indicating potential for future development and market opportunities.

Spark’s Take on TNXP Stock

According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.

Tonix Pharma’s strengths lie in its robust equity position and recent positive corporate events, including promising trial results and regulatory progress. However, ongoing profitability challenges and weak technical indicators weigh heavily on the stock score. The company’s growth phase and strategic advancements offer potential, but financial sustainability remains a concern.

To see Spark’s full report on TNXP stock, click here.

Tonix Pharma’s TNX-102 SL Advances in FDA Process

On March 24, 2025, Tonix Pharmaceuticals announced that the FDA will not require an Advisory Committee meeting for the New Drug Application of TNX-102 SL, a product candidate for fibromyalgia management. This development could streamline the approval process, potentially accelerating the product’s market entry and impacting the company’s operations and market positioning positively.

Tonix Pharma Secures Grant for TNX-801 Vaccine Development

On March 10, 2025, Tonix Pharmaceuticals announced receiving a $50,000 grant from the Medical CBRN Defense Consortium to support the development of its TNX-801 vaccine candidate for mpox and smallpox. The grant will aid in creating a commercialization plan for TNX-801, which has shown promising results, including being significantly less virulent than traditional smallpox vaccines and providing durable protection in animal models.

Tonix Pharma Appoints New Chief Technical Officer

On February 27, 2025, Tonix Pharma Limited, a subsidiary of Tonix Pharmaceuticals Holding Corp., signed an employment agreement with Siobhan Fogarty, the Chief Technical Officer. The agreement includes an annual salary, bonus eligibility, and equity compensation, with a 180-day notice period for termination, reflecting standard industry practices.

Tonix Pharma Highlights Fibromyalgia Treatment Success at Congress

On March 3, 2025, Tonix Pharmaceuticals presented data at the 7th International Congress on Controversies in Fibromyalgia, highlighting the effectiveness of their transmucosal sublingual cyclobenzaprine (TNX-102 SL) in reducing pain associated with fibromyalgia through improved non-restorative sleep. This presentation underscores Tonix’s commitment to addressing fibromyalgia and strengthens its position in the pharmaceutical industry by showcasing successful results from two Phase 3 studies.

Tonix Pharma Announces Promising Phase 1 Trial Results

On February 6, 2025, Tonix Pharmaceuticals announced encouraging Phase 1 trial results for its TNX-1500 product, a next-generation anti-CD40L monoclonal antibody, in healthy participants. The trial demonstrated that TNX-1500 was well-tolerated and effective in modulating immune responses, showing potential as a superior option in preventing organ transplant rejection with reduced toxicity compared to existing immunosuppressive treatments.